Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Tracon Pharmaceuticals, Inc. | tcon-ex322_275.htm |
| EX-32.1 - EX-32.1 - Tracon Pharmaceuticals, Inc. | tcon-ex321_276.htm |
| EX-31.2 - EX-31.2 - Tracon Pharmaceuticals, Inc. | tcon-ex312_277.htm |
| EX-31.1 - EX-31.1 - Tracon Pharmaceuticals, Inc. | tcon-ex311_278.htm |
| 10-K - 10-K - Tracon Pharmaceuticals, Inc. | tcon-10k_20171231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
|
|
(1)Registration Statement (Form S-8 No. 333-201808) pertaining to the 2011 Equity Incentive Plan, 2015 Equity Incentive Plan, and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc., (2)Registration Statement (Form S-8 No. 333-209592) pertaining to the 2015 Equity Incentive Plan, and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc., (3)Registration Statement (Form S-8 No. 333-216347) pertaining to the 2015 Equity Incentive Plan, and 2015 Employee Stock Purchase Plan of TRACON Pharmaceuticals, Inc., (4)Registration Statement (Form S-1 No. 333-216962) of TRACON Pharmaceuticals, Inc., and |
|
|
|
|
(5)Registration Statement (Form S-3 No. 333-209313) of TRACON Pharmaceuticals, Inc.; |
of our report dated February 28, 2018, with respect to the consolidated financial statements of TRACON Pharmaceuticals, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2017.
|
|
/s/ Ernst & Young LLP |
San Diego, California
February 28, 2018